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Abstract
Gastrointestinal endoscopy has evolved to become a therapeutic resource for 
multiple pathologic conditions, utilizing many techniques, tools and materials 
from the field of conventional surgery. Thermal, mechanical or chemical modali-
ties are often employed to expedite the process of hemostasis and achieve a stable 
 coagulum. Thermocoagulation coupled with devices for mechanical hemostasis 
have been adapted successfully to endoscopy. Chemical hemostasis from biomateri-
als can be obtained from biologically active materials such as thrombin and fibrin, 
absorbable products such as gelatins, collagen and oxidized cellulose or synthetic 
products and inorganic powders. Aside from hemostatic properties, biomateri-
als are also appealing due to its ability to promote wound healing. However, the 
use of biomaterials has not been as widespread in endoscopy as in conventional 
surgery, mainly because of the constraint of delivering these materials through an 
endoscope. Over the last decade, the options for biomaterials have expanded and its 
incorporation in endoscopy has slowly increased. Although the cost of biomaterials 
is higher compared to traditional hemostatics, this may be offset by the potential 
benefits of decreased bleeding related complications, procedure time, hospital stay 
and blood transfusions. Biomaterials have demonstrated an improvement in clinical 
outcomes during conventional surgery. Nevertheless, more studies are required to 
extrapolate these benefits to endoscopy.
Keywords: biomaterials, endoscopy, hemostasis, thrombin, fibrin sealant, gelatin, 
oxidized cellulose, collagen, acrylate polymers, hemostatic powders
1. Introduction
Although endoscopy can be traced back to ancient Greece, the Lichtleiter 
invented by Bozzini in 1805, is one of the earliest descriptions of endoscopy and 
established the basis of current endoscopy [1]. Further developments include the 
development of flexible endoscopes. However, endoscopy did not become wide-
spread until the invention of the fiber optic endoscope in the 1960s [2]. Endoscopic 
ultrasound (EUS) was developed in 1980 and constituted another innovatory 
development of endoscopy [3].
Initially a purely diagnostic procedure, gastrointestinal (GI) endoscopy has 
evolved to become a therapeutic resource for multiple pathologic conditions, 
utilizing many of the techniques, tools and materials successfully employed in 
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conventional surgery. A current advancement is natural orifice transluminal 
endoscopic surgery (NOTES) or incisionless surgery. First described in 2004, it 
uses endoscopic equipment to perform surgical procedures using natural orifices to 
access the peritoneal cavity, also known as “second space”. However, safe closure of 
the point of entry has been a concern. More recently, another concept developed in 
2007 and known as “third space” or submucosal endoscopy, has allowed access to the 
submucosal or intramural space, creating a mucosal safety valve, addressing one of 
the concerns of NOTES [2, 4].
Endoscopic surgery demands knowledge, skills and judgment that spans both 
surgery and gastroenterology training. It requires good knowledge of the patho-
physiology of the diseases, exceptional endoscopic skills, an in-depth understand-
ing of the anatomy, as well as the ability to manage the potential adverse events 
associated with the procedure. The standardization of technique has allowed to 
reduce the complexity associated with these procedures, currently being performed 
mostly in endoscopy suites, usually with less cost and less hospital stay [4].
2. Background
With the widespread use of anticoagulation and antiplatelet medication,  GI 
bleeding has become a common condition seen among  gastroenterologists, and 
achieving effective hemostasis is paramount to successful treatment. In GI bleeding, 
the combination of two hemostatic modalities has demonstrated superiority over 
single therapy. Furthermore, failed control of bleeding during the index endoscopic 
procedure or re-bleeding after successful hemostasis, significantly increases the risk 
of mortality, emphasizing the importance in  strategies to decrease this risk [5, 6].
Endoscopy has completely changed the approach to GI bleeding and has 
replaced surgery as the main modality of treatment. Hemostasis also constitutes one 
of the Halstedian principles of surgery and these principles can be extrapolated to 
endoscopic surgery [7].
Under normal circumstances the hemostatic process is always active and hap-
pens naturally as an interrelation between vessel contraction, platelets and coagula-
tion factors. Hemostasis can be divided into four stages: initiation, amplification, 
clot formation, consolidation and dissolution, and each stage is a prospective site 
for a therapeutic intervention to facilitate hemostasis. Hemostasis is initiated by 
vessel damage, triggered by tissue factor and collagen exposure at the site of injury. 
The amplification process is oriented to generate thrombin through various steps. 
Thrombin plays a central role in the clot formation stage by promoting the conver-
sion of fibrinogen to fibrin, which then creates a polymer that recruits platelets 
to form a stable clot and seal the site of vessel injury. Once the clot is formed, 
additional fibrin cross-linking is stimulated by factor XIIIa in order to consolidate 
the clot. Simultaneous to consolidation, the process of dissolution is started by a 
separate but interconnected system, with the conversion of plasminogen to plas-
min, causing the degradation of fibrin into smaller fragments (Figure 1) [8, 9].
Wound healing is regulated by the interplay of cellular, humoral and molecular 
processes and begins after tissue damage, at the same time that the coagulation 
cascade is initiated. There are three phases of wound healing:
1. Inflammatory phase in which cytokines recruit pro-inflammatory cells.
2. Proliferative phase whereby fibroblasts create bands of connective tissue rich 
in collagen.
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3. Remodeling phase, which can last for many years, and consists of the 
 granulation tissue transforming into vigorous scar tissue [10].
Additional methods are used to expedite the process of hemostasis and achieve a 
stable coagulum. In a broad sense, these methods fall into three categories: thermal, 
mechanical or chemical [6]. Thermocoagulation coupled with irrigation and aspira-
tion has been adapted successfully to endoscopic devices. Mechanical hemostasis in 
endoscopy is usually performed by using through the scope or over the scope clips, 
as well as detachable loops. Chemical hemostasis can be obtained from biomaterial, 
which are synthetic or natural substances that interact with the body, to replace 
tissues or augment its functions such as hemostasis and wound healing [6, 11, 12]. 
Biologically active materials such as thrombin and fibrin or absorbable products 
such as gelatins, collagen and oxidized cellulose have been used. Synthetic products 
and inorganic powder have also been employed in endoscopy. Besides the effects 
on the hemostatic process, many of these substances can have a positive or negative 
effect in the wound healing process [10].
Although the options for biomaterials have expanded over the last decades, 
the use of biomaterials to achieve chemical hemostasis has not been as widespread 
in endoscopy as in conventional surgery. One of the reasons is the restriction of 
delivering the biomaterial through the endoscope, and although most of the avail-
able options can be administered using through-the-scope injection or spraying 
catheters, other materials require to be grasped with endoscopic forceps and carried 
along the endoscope, to be delivered into the gut lumen [13–17]. The endoscopes 
are expensive medical equipment and endoscope damage is a genuine concern, 
especially with the use of acrylate polymers. It is recommended to flush the catheter 
immediately after acrylate use to prevent crystallization of the glue in the delivery 
needle. Dilution of the acrylate with lipiodol is also recommended to prevent 
potential clogging of the endoscopic channel [11, 18].
Figure 1. 
Biomaterials and their effects on hemostasis.




Thrombin is an enzyme with significant roles in hemostasis, inflammation and 
cell signaling. It has been used since the 1940s and can be obtained from bovine, 
pooled human plasma and recombinant sources. It has been used routinely since the 
1980s for hemostasis due to its effectiveness and ease of use [19].
Thrombin is commercially available alone and in combination with other 
 substances, usually delivered through endoscopic needles. The injection of any 
agent will likely have a mechanical effect during hemostasis by compressing the 
bleeding vessel, also known as tamponade effect. The main effect, however, is 
through a complex process that releases peptides from the alpha and beta chains 
from fibrinogen, which in turn polymerize by hydrogen bonding in a lateral and 
end-to-end fashion into an unstable fibrin clot. Further stabilization occurs by 
covalent cross-links promoted by factor XIIIa which promotes platelet aggregation 
and seals the bleeding [20, 21]. Thrombin can also induce vasoconstriction and 
chemotaxis of neutrophils and fibroblasts as well as the production of vascular 
endothelial growth factor [22]. Typically, thrombin is used in combination with 
other drugs such as epinephrine for vasoconstriction which has demonstrated to be 
superior to epinephrine alone. A study was performed in 140 patients presenting 
with severe GI bleeding from peptic ulcers to compare epinephrine to epinephrine 
plus thrombin. The combination of epinephrine plus thrombin obtained permanent 
hemostasis more often than epinephrine alone with decreased blood transfusion 
requirements and significant reduction in mortality [23]. However, a similar study 
was performed in 64 patients which did not show any benefits from thrombin, 
although the dose of thrombin in this study was significantly less than the first 
study (150–300 IU vs. 600–1000 IU) [24]. Other studies have used a mixture of 
epinephrine and thrombin sprayed into the ulcer bed; however, this approach 
did not show any benefits [23]. The use of thrombin has also been reported in 
the treatment of gastric varices since 1947 [25]. Although variceal band ligation 
treatment is effective for bleeding from esophageal varices, the use of banding for 
gastric varices is limited. Gastric varices are present in 15 to 100% of patients with 
esophageal varices, and although less prone to bleeding, when bleeding does occur, 
it is often more severe with high rebleeding rates and is more challenging to achieve 
effective hemostasis. Currently the main modality of treatment for gastric varices is 
acrylate injection, however its use it typically limited to highly specialized centers 
given its increased risk of systemic embolization and difficulty in administration 
and the potential to cause damage to the endoscope. Direct injection of thrombin 
is another method that has been explored for the treatment of varices. This agent is 
most commonly delivered through endoscopic needles. Multiple series have docu-
mented its safety and efficacy achieving hemostasis in almost all patients, although 
no randomized trials have compared it to the other treatment modalities available 
[25–27]. Advances in EUS have allowed successful EUS guided thrombin injection, 
with theoretical less risk of systemic embolization since the feeding vessel can be 
identified under visualization, requiring less amounts of thrombin than direct 
injection with regular endoscopy [28].
3.1.1 Adverse effects
Due to its biologic nature, thrombin can be highly immunogenic and allergic 
reactions and autoimmune phenomena have been reported, especially with the 
bovine derived thrombin. Recombinant thrombin is less immunogenic than bovine 
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and human, but there is still a possibility of cross-reaction if a patient has had 
previous exposure to the other types of thrombin with resultant antibody formation 
[20, 22]. In regards to human thrombin, it is isolated from pooled plasma donors 
and there is always concern for transmission of blood-borne pathogens such as HIV 
and viral hepatitis as well as the theoretical risk of prion disease [29]. The use of 
thrombin has been associated with coagulopathy and abnormal laboratory results 
such as prothrombin time and partial thromboplastin time [19, 27]. The develop-
ment of autoantibodies against factor V may precipitate paradoxical bleeding after 
thrombin injection [30, 31]. With the injection of thrombin directly into a vessel, it 
clots the fibrinogen of blood immediately and there is concern for distant emboliza-
tion, however its use appears to be safe based on small studies [29].
3.1.2 Future directions
Currently US and European guidelines recommend acrylate injection as the ini-
tial modality of treatment for bleeding gastric varices and do not include thrombin 
[32, 33]. However, thrombin alone as well as in combination with gelatin matrices, 
has demonstrated to be effective, safe and easy to administer, contrary to sclerosing 
agents and acrylate. With thrombin, there is no risk of secondary bleeding from 
post injection ulceration, and constitutes a true alternative to acrylate [26, 28].
3.2 Fibrin
Fibrin sealant has been widely used as a tissue adhesive for non-suture closure 
of lesions, mimicking the last steps of the coagulation cascade where fibrinogen is 
converted to fibrin.
Fibrinogen is the main component in fibrin sealants and is a dimer with  identical 
units formed by three polypeptide chains (α, β and γ) [34]. Thrombin is the only 
coagulation factor that can cleave fibrinogen into fibrin which then assemble into 
fibrils that will form a three-dimensional network. This network is further stabi-
lized by factor XIIIa by initiating new peptide unions known as gamma-gamma 
dimmers to form the alpha-polymers, a process assisted by the presence of calcium. 
Factor XIIIa also induces crosslinking of plasmin inhibitors to protect the clot from 
fibrinolysis by plasmin. Once the fibrin net is formed, it attracts cells and functions 
as a scaffold to stimulate granulation tissue and facilitate wound healing. Fibrin 
also has high affinity to collagen and cell surface receptors such as integrins, which 
facilitate adherence to wound surfaces [21, 30, 34, 35].
The composition of multiple presentations of fibrin available in the market is 
variable and neither the concentration or purity of the components is uniform. 
Usually the product is available as a two-component kit consisting of separate 
fibrinogen and thrombin which acts as an activator of fibrin. Calcium is always 
combined with one of the components. Factor XIII, a clot stabilizer, and aprotinin 
or tranexamic acid acting as fibrinolysis inhibitors, are also included in the fibrino-
gen containing mixture. The significant variation in components of these avail-
able products affects their qualities such as viscosity, adherence force of the clot, 
mechanical strength, speed of clotting and resistance to proteolysis [21, 34, 36, 37].
Fibrin has been used extensively across an extensive range of surgical proce-
dures, providing bleeding control, suture support and sealing. It has been available 
in Europe and Japan since the 1970s, but did not receive regulatory approval in the 
United States until 1998, still however, its use is not widespread in endoscopic pro-
cedures [37–39]. Most of the initial reports of the use of fibrin sealant were in the 
treatment of upper GI bleeding from peptic ulcer disease, delivered using injection 
needles in a similar fashion as thrombin. Although the studies showed conflicting 
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data in terms of benefits, fibrin was not shown to be superior to  epinephrine 
injection alone [38, 40, 41]. Intravariceal injection of fibrin has also been reported 
for bleeding gastric varices showing efficacy to control bleeding with low risk of 
rebleeding [42].
Postoperative fistulas are secondary to a broad range of factors and are relatively 
common complications after surgery. While most fistulas respond to conservative 
management, healing is unlikely after 6 weeks and persistent fistulas are associated 
with increased morbidity and mortality from malnourishment and septic compli-
cations. Endoscopy has been used in the treatment of persistent enterocutaneous 
fistulas as an alternative to surgery. Fibrin application coupled with debridement 
of the epithelized fistulous tract and ablation of the mucosa at the internal open-
ing has been used successfully for endoscopic sealing of the fistulous tract. Fistula 
occlusion intends to halt further passage of secretions, but also fibrin may have a 
role in stimulating wound healing by promoting fibroblast proliferation and forma-
tion of new blood vessels. Nonetheless, the studied populations are quite heteroge-
neous and the reported success has wide variability from 36–100% [39, 43–48]. The 
same technique has been used for the closure of gastrocutaneous fistulas that failed 
to close after gastrostomy tube removal [49].
With third space endoscopy, large amounts of tissue can be resected en-bloc 
using electrosurgical knives. However, bleeding and/or perforation are serious 
adverse event, especially in patients with resection size larger than 4 cm or taking 
antiplatelet or anticoagulants [16, 50]. When perforation results after ESD, the 
endoscopic options include endoscopic clips or suturing. The utility of clips is of 
limited use when dealing with large tissue defects. While suturing can close large 
defects, its use may be disadvantageous when the tissue is friable or the layers 
are thin such as in the duodenum. A new method of “tissue shielding” has been 
described to treat large ulcers or perforations induced by endoscopic submucosal 
dissection (ESD), with this technique sheets of polyglycolic acid are applied to 
the ESD area and then the sheet is coated with fibrin sealant. This method has 
demonstrated in retrospective studies, to be effective as well as simple and safe, 
even in patients under continued use of antiplatelets or anticoagulants, avoiding 
the morbidity of an emergency surgery [51–56]. The use of this technique has also 
demonstrated decreased risk for delayed complications such as stricture, since the 
defect is covered rather than closed, with results comparable or even better than 
with the use of systemic or intralesional injection of steroids, without the side 
effects associated to the use of steroids [13, 57, 58]. On the other hand, a prospective 
randomized study, did not show any benefit in the prevention of bleeding from 
the use of polyglycolic acid sheet and fibrin sealant after ESD in the stomach, in 
patients with high risk for bleeding [50].
A fibrin sealant spray alone has also been used during ESD for early gastric 
 cancer, this modality of treatment was compared to standard thermal and mechani-
cal hemostasis and showed less bleeding and earlier wound healing in the fibrin 
group, since micro vessels were less affected in the fibrin sealant group due to 
limited use of thermal coagulation [59, 60].
3.2.1 Adverse effects
Coagulopathy secondary to thrombin, which is included in the fibrin sealant 
has been widely documented. Aprotinin may also be present in some versions of 
fibrin sealants and since it is obtained from a bovine source, it includes the risk of 
anaphylaxis. Although aprotinin may be valuable when fibrinolysis is high, it is not 
considered an absolute requirement for the success of the sealant and aprotinin free 
versions eliminate that risk [37]. Commercially available fibrin is obtained from 
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multidonor blood products and HIV transmission after the use of fibrin has been 
reported in the past and the risk for other blood borne infections is also a theoretical 
risk. Presently, the available sealants in the market are virally inactivated and this 
risk is practically inexistent [21].
3.2.2 Future directions
Fibrin sealant is a versatile product that has multiple properties useful not 
only for hemostasis but also to promote wound healing, and currently is probably 
being underused and oftentimes misused. The ability to recreate the last stage 
of the coagulation mechanism allows its use as a lifesaving treatment in patients 
with coagulopathies. However, its use should not be limited to those patients and 
its use has been described more frequently during endoscopic procedures [21]. 
Heterologous fibrin sealants which will decrease costs and risk of blood related 
infections are currently under development [36].
3.3 Gelatins
Gelatin is a hemostatic agent made from hydrolyzed and purified animal 
collagen (swine, sheep or equine dermis or tendon). Its use in hemostasis was first 
reported by Correll in 1945 [61]. Capable of absorbing up to 45 times its weight of 
whole blood, it has become commonplace in surgery for hemostatic intervention 
[62]. Since its introduction, few advances in its composition have been made and is 
available in sponge, powder and solution forms. It has also been used in conjunc-
tion with other products that aid in hemostasis such as thrombin and tranexamic 
acid. Although its mechanism of action is not fully known, it is believed to act more 
physically than chemically, however it has been theorized that the clotting effect of 
gelatin sponge may be due to the release of thromboplastin from damaged platelets 
while coming into contact with the walls of the sponge upon entering, which then 
interacts with prothrombin and calcium, producing thrombin and initiating the 
clotting cascade [63].
It is currently indicated as a hemostatic device in surgical interventions, when 
control of capillary, venous, and arteriolar bleeding is not possible by conventional 
procedures. It has also been a basic embolic material particularly used in interven-
tional radiology (IR) for various disease entities such as hypervascular tumors, 
bleeding, and preoperative embolization, showing to be quite effective. However, 
experience in the field of GI endoscopy is limited. In fact, most experience comes 
in the form of case reports. One case series describes successful EUS-guided coil 
injection in combination with hemostatic absorbable gelatin sponge for treatment 
of bleeding gastric varices [64]. In another case, IR embolization failed to achieve 
hemostasis in a patient with hemorrhagic shock due to an arterial hemorrhage at 
an oversewn bile duct stump after liver transplantation, and a gelatin slurry was 
applied into the bile duct stump during endoscopic retrograde cholangiopancrea-
tography, achieving control of the bleeding [65].
Hemostatic gel matrices have been used as hemostatic agents during surgery that 
requires atraumatic hemostasis due to its safety and ease of use. They are composed 
of a flowable gelatin matrix of either bovine or swine origin and thrombin. The 
fluidity of the matrix offers the benefit of adapting to the shape of the wound site 
allowing full tissue contact. While the matrix promotes passive hemostasis from 
mechanical compression and platelet aggregation, the addition of thrombin will 
promote the coagulation process by the mechanism discussed previously, and 
these agents combined may also facilitate the healing process [66–68]. Since these 
hemostatic agents require platelet aggregation, their use is not recommended in 
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patients with thrombocytopenia. However, they have demonstrated efficacy even in 
patients with recent use of antiplatelet agents or anticoagulation. Matrices provide 
hemostasis in about 5 minutes and are usually absorbed from 4 to 8 weeks [68].
Like gelatins, the use of hemostatic matrices in endoscopy has been limited. Its 
use was extrapolated from IR procedures for varices such as coil-assisted retrograde 
transvenous obliteration. The reported use of matrices is mainly as adjuvant therapy 
with coiling during EUS guided embolization of gastric varices. The potential 
benefits of this absorbable material are the lack of post injection ulceration that 
has been associated with acrylate injection as well as the ease of administration [69, 
70]. Small series have compared both modalities of treatment showing high techni-
cal and clinical success with no rebleeding after 9 months with the use of coils/
hemostatic matrix, compared to rebleeding in 38% of patients in the acrylate group. 
There was also a decrease in the transfusion requirements and adverse events after 
the use of the coils/hemostatic matrix [64, 69, 70]. No intraprocedural complica-
tions were reported with the coils/hemostatic matrix, and the only minor adverse 
events of abdominal pain were likely related to the procedure itself [70].
One of the constraints of the fluidity of the hemostatic matrices is the need 
to keep the matrix in direct contact with the bleeding surface until hemostasis is 
achieved. Recently another concept of hemostatic matrix delivery has been reported 
in animals, accomplished with the use of a special applicator consisting of a nitinol 
mesh coated with plastic. The applicator has angular variation up to 45 degrees that 
allows to keep the matrix in the desired place until achieving clot formation [71].
3.3.1 Adverse effects
Although uncommon, allergic reaction to gelatins has been reported [72].
The reported adverse effects are dependent on the location and purpose of 
its use and include: infection, abscess formation, granuloma and compression of 
adjacent structures when used in a closed space [73]. Organ infarction has been 
reported when used for embolization [74].
3.3.2 Future directions
While the use of gelatin in hemostasis goes back to the mid 20th century, its 
application has certainly evolved and gained attention in the different fields of 
medicine, particularly surgery and intervention radiology. While there are promis-
ing case reports in the GI endoscopic literature, further studies are needed to see if 
this is an effective and viable option for endoscopic hemostasis.
3.4 Oxidized cellulose
Oxidized cellulose (OC) has been used clinically as a hemostatic agent since the 
1940s [75, 76]. Cellulose is a polysaccharide of glucopyranose united by β-glucosidic 
bonds. It can be produced by two methods: using a regenerated process that forms 
organized fibers; and a non-regenerated process where fibers remain unorganized. 
Its synthesis involves multiple steps and the final product is oxidized to make 
it absorbable by the tissues, this process also gives its low pH to cellulose and is 
responsible for its hemostatic and bactericidal properties. The low pH of the physi-
cal matrix promotes platelet aggregation to form a blood clot, and the acid milieu 
generated by the carboxylic group cannot be survived by many gram-positive and 
gram-negative bacteria, including antibiotic resistant strains [76, 77]. However, 
this feature may be disadvantageous since the acidity makes OC cytotoxic, with 
detrimental effects on erythrocytes causing some hemolysis and affecting wound 
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healing, since acidity prevents the proliferation of fibroblast and halts the contrac-
tion of the extracellular matrix. OC also has the ability to absorb fluids and can have 
a tamponade effect during hemostasis [75–78]. Although non-regenerated OC may 
have superior hemostatic performance, the main difference between regenerated 
and non-regenerated OC lies in the way they are absorbed. Regenerated OC degra-
dation starts within 18 hours of implantation via β-elimination by glycosidases and 
is fully absorbed in 7–14 days, while non-regenerated OC requires phagocytosis and 
then hydrolysis by macrophages through a longer process [10, 76, 78].
OC is used when conventional hemostasis is not effective or practical and is the 
chemical hemostatic agent most commonly used worldwide because it is cost-effective, 
easy to use, atraumatic, biocompatible, absorbable and bactericidal [10, 75, 76].
Simultaneous administration of organic hemostatics such as thrombin and/or 
fibrin to enhance the hemostatic properties of cellulose is purposeless since the low 
pH denatures the proteins and they become ineffective [76].
The use of OC in the treatment of active GI bleeding from ulcers and angiodys-
plasia has been reported in the literature [79, 80].
The concept of “tissue shielding” reported with the use of thrombin and a 
sheet of polyglycolic acid has been used with OC in animal models and recently in 
humans. With this technique, a fragment of hemostatic is placed over the mucosal 
defect to prevent bleeding after ESD has been carried out [81, 82].
Cellulose requires dry application, although a new modality of delivery has been 
described recently during bleeding prevention following ESD, where OC is deliv-
ered via endoscopic spraying after being mixed with saline in a syringe [15, 83].
3.4.1 Adverse effects
Although the acidity associated with the oxidized cellulose has antibacterial 
properties, it should be used with caution in an infected wound since the presence 
of a foreign body may increase the predisposition to infection or formation of 
granulomas [36, 73]. However, infection is probably less of a concern in the GI tract 
since it is not a sterile space. Due to its low pH, oxidized cellulose can either provoke 
a strong inflammatory reaction or delay wound healing by decreasing the number 
of fibroblasts, and it is recommended to remove any excess product once hemostasis 
is achieved [73]. There are documented reports of migration of oxidized cellulose 
through suture lines provoking fistulation [84].
3.4.2 Future directions
Although many of the properties of oxidized cellulose make it an attractive 
hemostatic product. Its use in GI endoscopy is limited to few case reports, mainly 
because of the constraint of delivering the product through the endoscope. And 
although the hemostatic effect of OC is better when applied dry, the reported use of 
OC by spraying has demonstrated good results and may increase its use during GI 
procedures.
3.5 Collagen
Collagen is a three-polypeptide chain (α-chains) characterized by the  presence 
of one or more triple-helical domains and serves as a structural scaffold in  tissue 
because of its stiff structure which is essential for tissue integrity. It plays an 
important role in hemostasis during injury, via interaction with Von Willebrand 
factor, integrins and clotting factors. Collagen is in the matrix underlying vascular 
endothelial cells. An injury will result in exposure of blood flow to subendothelial 
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structures that contain a high percentage of collagen which results in activation 
of platelets and the intrinsic coagulation pathway. Platelets bind to collagen via 
glycoprotein receptors, inducing a negative charged lipid to become exposed to the 
platelet membrane, exposing procoagulant phospholipids, leading to the change of 
shape reaction, triggering irreversible platelet aggregation and thrombosis. Various 
studies have also demonstrated administration of collagen could aid in wound 
healing by activation of inflammatory cells and increased vascularization of injured 
tissue [35, 85].
In the US, collagen-based products are being used in surgical hemostasis since 
the 1970s [86]. Hydrolyzed collagen is available as a viscous, amber aqueous solu-
tion or most commonly used as white hygroscopic powder. It is commercially 
prepared from many sources but mainly from bovine or porcine sources. Sponges 
incorporating collagen are manufactured by several companies to achieve hemo-
stasis for surgical procedures, however, there is limited literature regarding the use 
of collagen for hemostasis during endoscopic procedures. Several case reports and 
small case series have demonstrated successful management of GI bleeding with 
use of collagen spray. A prospective study of 18 patients demonstrated collagen 
spray is safe and an effective hemostatic agent in treating peptic ulcers with Forrest 
classification category 1a and 1b. The collagen spray was used for patients that 
failed conventional therapy due to poor visualization or persistent bleeding after 
application of therapy. The collagen spray kit consists of an air pump, probe, a 7.5 Fr 
spray catheter, and a pre-loaded collagen cartridge containing five grams of powder. 
The spray catheter was passed through the working channel of the endoscope. One 
gram of collagen powder was delivered at a time over 10s, with the distal end of the 
catheter 2 to 3 cm from the lesion with maximum of 2 gram for the bleeding site. 
Endoscopy in this study was repeated after 24 to 48 hours, confirming treatment 
success [14].
Collagen injection has also been used in the treatment of a radiation induced 
broncho-esophageal fistula, injection in the submucosa around the fistula was 
performed using a standard endoscopic needle achieving closure of the fistula [87].
3.5.1 Adverse effects
Limited studies exist for GI bleeding, but extensive experience and literature is 
available in the field of surgery. There are no major side effects reported and poten-
tial allergic reaction is possible since most formulations are derived from bovine or 
porcine source.
3.5.2 Future direction
There is extensive surgical literature to support use of collagen-based products 
for hemostasis. Collagen spray has been successful in treating GI bleeding sec-
ondary to peptic ulcer disease, but larger studies are required to investigate this 
further, and also to see if its application would be beneficial in other sources of GI 
bleeding.
3.6 Acrylate polymers (glue)
Acrylate is a liquid monomer that can rapidly polymerize when in contact with an 
ionic medium like water, blood or tissue proteins. The polymer forms a strong adhe-
sive bond to tissues with sealing properties, satisfying the definition of biomaterial. 
Because of the rapid polymerization, it can be combined with an ethiodized oil like 
Lipiodol. This combination has the advantage of prolonging the polymerization 
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time, controlling the speed of solidification, reducing the risk of embolization 
and opacifying the liquid, which allows it to be radio-opaque under fluoroscopy. 
However, injection of undiluted cyanoacrylate is also performed [11, 88].
Acrylate has been widely used for bleeding gastric varices and is the first line 
treatment for bleeding fundal varices, achieving hemostasis in more than 90% of 
the cases.
Studies have also demonstrated the efficacy of acrylate achieving hemostasis 
in refractory non-variceal GI bleed, usually after trying epinephrine injection, 
cauterization and/or endoscopic clips, prior to IR or surgical interventions [89–91]. 
Its usefulness has been demonstrated in peptic ulcer bleeding refractory to con-
ventional hemostatic measures and also in the treatment of rectal ulcers. It has 
also been able to achieve hemostasis for Dieulafoy’s lesion that failed hemostasis 
with epinephrine and bipolar cautery. Acrylate is an effective mode of treatment 
for bleeding ectopic varices, especially those located in the antrum as well as the 
duodenum, and has also demonstrated efficacy in controlling bleeding from oozing 
gastric vascular ectasia after argon plasma coagulation and endoscopic clips have 
failed. Furthermore, it has shown favorable outcomes in bleeding from tumor inva-
sion into the intestinal wall.
Injections of acrylate are delivered endoscopically using a standard forward 
viewing video-endoscope via injection catheters. A 1:1 ratio of acrylate is mixed 
with Lipiodol and this is injected as a bolus. The tip of the endoscope and the 
accessory channel can be treated with silicone oil to prevent endoscopic damage, 
other studies have used Teflon catheters. Some studies also suggest that spraying 
acrylate directly over the bleeding point might be better than injection [11, 18]. A 
standardized injection technique was developed for the use of acrylate, performed 
using a Luer lock injection needle catheter. To minimize the risk of systemic 
embolization, it is recommended that not more than 1 mL of the acrylate/Lipiodol 
solution be injected into the tissue each time, multiple injections can be used but 
the maximum volume of each injection should be 1 mL. The dead space volume 
of the needle catheter should be measured and the needle should not be primed 
with glue before injection. A ‘sandwich’ technique has been described where the 
injecting catheter is primed with Lipiodol and Lipiodol-acrylate-Lipiodol solu-
tion is injected [92]. After injecting the glue, a second injection of distilled water 
is recommended, the volume of which should be the dead space volume of the 
needle catheter. This is done to deliver the entire glue from the catheter. When 
used for varices, the varix must then be probed to ensure obliteration. If the varix 
remains soft, another injection of 1 mL must be given [93]. Coils delivered with 
EUS assistance can also be used along with acrylate to provide a structure for 
localized acrylate  polymerization [70].
3.6.1 Adverse effects
After injection, the vessel plug formed by the polymer of acrylate will be 
expelled from the varix as early as one week and up to a year after the procedure and 
rebleeding may occur [11]. Although rarely reported, the needle can get trapped in 
the varix due to rapid polymerization of the acrylate with inability to withdrawn the 
needle from the varix and/or unroofing of the varix [70]. One of the major compli-
cations of acrylate polymers is systemic embolization. Although rare, this can be 
potentially lethal. It is most commonly seen when acrylate is used for the treatment 
of isolated gastric varices type 1 [94].
Systemic embolization can lead to portal and splenic vein thrombosis, 
 pulmonary embolism and splenic infarction. Transient bacteremia was noted in 
clinical studies especially in patients with advanced liver disease. Recurrent sepsis is 
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rare but has been reported. In patients with a patent foramen ovale, systemic embo-
lization can lead to stroke. This can be prevented by injecting no more than 1 mL of 
the acrylate/Lipiodol solution. Duodenal ulcer perforation has also been described 
after using acrylate to control bleeding duodenal ulcers [36, 41]. Necrosis of the 
vessel wall with perivascular inflammation has also been described and is supposed 
to be related to a foreign body reaction [11].
3.6.2 Future directions
Acrylate has multiple properties that make it an efficient hemostatic agent. It 
is a relatively safe and easy to use agent, already established as first line treatment 
for gastric varices and has also demonstrated efficacy in non-variceal bleeds that 
are refractory to conventional methods. It can be considered prior to IR or surgical 
intervention for refractory GI bleeding using the above technique, especially in 
patients who would be poor surgical candidates. Given its inexpensive cost and ease 
of use, it can be considered as a second line hemostatic agent for non-variceal GI 
bleeding that is refractory to conventional methods.
3.7 Mineral powder
For years, inert mineral powders have been used by military medical personnel 
for achieving hemostasis in the field [95]. A proprietary mineral powder based on 
Bentonite clay has been developed and works in two different ways: as a mechani-
cal barrier and by absorption. When in contact with the bleeding site, the powder 
forms a barrier over the vessel wall, quickly stopping the bleeding, and secondly, 
the absorbent powder increases the local concentration of clotting factors and 
enhances clot formation [96]. Last, it has also been postulated that the mineral 
powder may activate the clotting cascade along with aggregating platelets, forming 
a fibrin plug [97]. Given the lack of systemic absorption, the coagulum then falls off 
after 24–72 hours and is eliminated through the GI tract [98].
The mineral powder is available as a kit containing a hand-held device including 
a pressurized CO2 canister, a through-the-scope delivery catheter (10-Fr or 7-Fr), 
and a reservoir for the 21-g powder cartridge. The powder is delivered via push 
button in 1- to 2-second bursts until hemostasis is achieved. Up to three kits can be 
used in each patient. It has been evaluated for its safety and efficacy in numerous 
studies for the primary, adjunctive and rescue therapy of non-variceal gastrointes-
tinal bleeding including: peptic ulcers, post-polypectomy bleeding, post endoscopic 
mucosal resection or dissection bleeding, gastric antral vascular ectasia, Dieulafoy’s 
lesions, Mallory-Weiss tears and tumor bleeding [99].
3.7.1 Adverse effects
Rare adverse events associated to the use of the mineral powder may include 
embolism, intestinal obstruction, and allergic reaction to its components [100]. 
However, given the relatively low-pressure system used in the canister during 
deployment of the powder, the risk of embolism is minimal [96]. Reports of 
hemostatic powder dislodgement from the GI mucosa approximately 48 hours after 
its use may theoretically cause intestinal obstruction [98]. However, review of the 
literature did not reveal any of these potential adverse events. Because the mineral 
powder cannot be taken in by mucosal tissues, absorption and metabolism of the 
powder does not occur in the body, thereby nearly eliminating the risk of systemic 
toxicity. Since the mineral powder does not contain human or animal proteins or 
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botanicals and has no known allergens, it has been shown to have minimal side 
effects [98, 99].
3.7.2 Future directions
The advantages of the mineral powder are that, unlike traditional techniques, 
it is non-contact, non-thermal and does not require specific targeting making 
endoscopic application easier. In a summary of 19 studies comprising treatment of 
234 patients with the hemostatic mineral powder, the combined rate of successful 
hemostasis was 88.5%. Rebleeding occurred within 72 hours in 16.2% after suc-
cessful initial hemostasis [100]. Given the above, it is a welcomed addition to the 
endoscopic armamentarium to treat GI bleeding.
Head to head randomized controlled trials compared to more traditional hemo-
static therapy (i.e. endoscopic clips, epinephrine injection, and thermal coagula-
tion) would truly help discern the role of mineral powder in achieving endoscopic 
control of GI bleeding.
3.8 Polysaccharides
Another option for endoscopic hemostasis comes in the form of plant-based 
polysaccharide components and two such products are available currently. When 
the polysaccharide powder come into contact with blood it absorbs water, increas-
ing the concentration of platelets and clotting factors, resulting in an accelerated 
clotting cascade. Additionally, it forms a gel-like matrix that adheres to the bleeding 
lesion, providing a mechanical barrier. Both available products have almost an 
instantaneous effect on hemostasis upon contact and since they are plant-starch 
derived, it is degraded and absorbed naturally by digestive enzymes within 
hours [101, 102].
Presently these products have been studied for endoscopic use in GI  bleeding 
and there are case reports about successful use as salvage therapy in post- 
necrosectomy bleeding [17]. Current indications include upper and lower GI 
bleeding caused by ulcer, post polypectomy, tumor, post endoscopic mucosal 
dissection/ESD, in-stent, Mallory-Weiss tear, etc. [99]. It is deployed using com-
pressed air through an endoscopic catheter. In 21 patients, the use of polysaccharide 
successfully achieved hemostasis in all patients when conventional therapy using 
dual or triple therapy had failed [101]. Another study looked at the use of polysac-
charide powder in 22 patients and found to have success in 21/22 patients of which 
16 patients underwent primary hemostasis with the polysaccharide [103].
3.8.1 Adverse effects
Similar to mineral powder, the side effect profile of polysaccharide based topical 
agents include theoretical side effects of embolism, intestinal obstruction and 
allergic reaction, however there are no reported cases.
3.8.2 Future directions
The use of hemostatic powders certainly has its advantages when compared 
to conventional modalities of endoscopic hemostasis. The hemostatic powders 
have been shown to be effective in upper and lower GI bleeding and as primary 
and salvage or bridge therapies. Polysaccharide and mineral powders have no 
differences when assessing short term and long-term hemostasis and rebleeding 
[99]. However, the majority of studies particularly looking at the polysaccharide 
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based topical therapies have been small and focused on adjunctive therapy. 
Further randomized studies are needed to assess the role of this type of hemostatic 
intervention.
4. Conclusion
Biomaterials have demonstrated proven efficacy and improved clinical  outcomes 
in conventional surgery. And although the cost of these materials is higher 
compared to traditional hemostatics, it may be offset by the possible benefits of 
decreased bleeding related complications, procedure time, hospital stay and blood 
transfusion.
Given the advances in endoscopy over the past few decades, and healthcare 
leaning towards more minimally invasive first line therapies, the migration of these 
concepts to GI endoscopy is well positioned and likely much welcomed by endos-
copists around the world. While the use of these agents has certainly expanded 
exponentially over the past decade, the use and prior descriptions of biomaterials 
in endoscopy is particularly limited, considering the full array of potential applica-
tions of these substances. Most of the reported uses of biomaterials in endoscopy 
are actually “off label” and more studies are required to allow for better understand-
ing and decision-making guidance to best aid in patient care.
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